PARP Cancer Research Results

PARP, poly ADP-ribose polymerase (PARP) cleavage: Click to Expand ⟱
Source:
Type:
Poly (ADP-ribose) polymerase (PARP) cleavage is a hallmark of caspase activation. PARP (Poly (ADP-ribose) polymerase) is a family of proteins involved in a variety of cellular processes, including DNA repair, genomic stability, and programmed cell death. PARP enzymes play a crucial role in repairing single-strand breaks in DNA.
PARP has gained significant attention, particularly in the treatment of certain types of tumors, such as those with BRCA1 or BRCA2 mutations. These mutations impair the cell's ability to repair double-strand breaks in DNA through homologous recombination. Cancer cells with these mutations can become reliant on PARP for survival, making them particularly sensitive to PARP inhibitors.
PARP inhibitors, such as olaparib, rucaparib, and niraparib, have been developed as targeted therapies for cancers associated with BRCA mutations.

PARP Family:
The poly (ADP-ribose) polymerases (PARPs) are a family of enzymes involved in a number of cellular processes, including DNA repair, genomic stability, and programmed cell death.
PARP1 is the predominant family member responsible for detecting DNA strand breaks and initiating repair processes, especially through base excision repair (BER).

PARP1 Overexpression:
In several cancer types—including breast, ovarian, prostate, and lung cancers—elevated PARP1 expression and/or activity has been reported.
High PARP1 expression in certain cancers has been associated with aggressive tumor behavior and resistance to therapies (especially those that induce DNA damage).
Increased PARP1 activity may correlate with poorer overall survival in tumors that rely on DNA repair for survival.
Scientific Papers found: Click to Expand⟱
2800- CHr,    Chrysin Activates Notch1 Signaling and Suppresses Tumor Growth of Anaplastic Thyroid Carcinoma In vitro and In vivo
- in-vitro, Thyroid, NA
TumCG↓, NOTCH↑, cl‑PARP↑, Apoptosis↑,
2804- CHr,  Rad,    Gamma-Irradiated Chrysin Improves Anticancer Activity in HT-29 Colon Cancer Cells Through Mitochondria-Related Pathway
- in-vitro, CRC, HT29
RadioS↑, ROS↑, MMP↓, Casp3↑, Casp9↑, cl‑PARP↑,
2807- CHr,    Evidence-based mechanistic role of chrysin towards protection of cardiac hypertrophy and fibrosis in rats
- in-vivo, Nor, NA
*antiOx↑, Inflam↓, *cardioP↑, *GSH↑, *SOD↑, *Catalase↑, *GAPDH↑, *BAX↓, *Bcl-2↑, *PARP↓, *Cyt‑c↓, *Casp3↓, *NOX4↓, *NRF2↑, *HO-1↑, *HSP70/HSPA5↑,
2785- CHr,    Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin
- Review, Var, NA
*NF-kB↓, *COX2↓, *iNOS↓, angioG↓, TOP1↓, HDAC↓, TNF-α↓, IL1β↓, cardioP↑, RenoP↑, neuroP↑, LDL↓, BioAv↑, eff↑, cycD1/CCND1↓, hTERT/TERT↓, MMP-10↓, Akt↓, STAT3↓, VEGF↓, EGFR↓, Snail↓, Slug↓, Vim↓, E-cadherin↑, eff↑, TET1↑, ROS↑, mTOR↓, PPARα↓, ER Stress↑, Ca+2↑, ERK↓, MMP↑, Cyt‑c↑, Casp3↑, HK2↓, NRF2↓, HO-1↓, MMP2↓, MMP9↓, Fibronectin↓, GRP78/BiP↑, XBP-1↓, p‑eIF2α↑, *AST↓, ALAT↓, ALP↓, LDH↓, COX2↑, Bcl-xL↓, IL6↓, PGE2↓, iNOS↓, DNAdam↑, UPR↑, Hif1a↓, EMT↓, Twist↓, lipid-P↑, CLDN1↓, PDK1↓, IL10↓, TLR4↓, NOTCH1↑, PARP↑, Mcl-1↓, XIAP↓,
2786- CHr,    Chemopreventive and therapeutic potential of chrysin in cancer: mechanistic perspectives
- Review, Var, NA
Apoptosis↑, TumCCA↑, angioG↓, TumCI↓, TumMeta↑, *toxicity↓, selectivity↑, chemoPv↑, *GSTs↑, *NADPH↑, *GSH↑, HDAC8↓, Hif1a↓, *ROS↓, *NF-kB↓, SCF↓, cl‑PARP↑, survivin↓, XIAP↓, Casp3↑, Casp9↑, GSH↓, ChemoSen↑, Fenton↑, P21↑, P53↑, cycD1/CCND1↓, CDK2↓, STAT3↓, VEGF↓, Akt↓, NRF2↓,
1593- Citrate,    Citrate Induces Apoptotic Cell Death: A Promising Way to Treat Gastric Carcinoma?
- in-vitro, GC, BGC-823 - in-vitro, GC, SGC-7901
PFK↓, Glycolysis↓, tumCV↓, cl‑Casp3↑, cl‑PARP↑, Apoptosis↑, ATP↓, ChemoSen↑, Mcl-1↓, glucoNG↑, FBPase↑, OXPHOS↓, TCA↓, β-oxidation↓, HK2↓, PDH↓, ROS↑,
1580- Citrate,    Citrate activates autophagic death of prostate cancer cells via downregulation CaMKII/AKT/mTOR pathway
- in-vitro, Pca, PC3 - in-vivo, PC, NA - in-vitro, Pca, LNCaP - in-vitro, Pca, WPMY-1
Apoptosis↑, Ca+2↓, Akt↓, mTOR↓, selectivity↑, TumCP↓, cl‑Casp3↑, cl‑PARP↑, LC3‑Ⅱ/LC3‑Ⅰ↑, p62↓, ATG5↑, ATG7↑, Beclin-1↑, TumAuto↑, CaMKII ↓,
1576- Citrate,    Targeting citrate as a novel therapeutic strategy in cancer treatment
- Review, Var, NA
TCA↓, T-Cell↝, Glycolysis↓, PKM2↓, PFK2?, SDH↓, PDH↓, β-oxidation↓, CPT1A↓, FASN↑, Casp3↑, Casp2↑, Casp8↑, Casp9↑, cl‑PARP↑, Hif1a↓, GLUT1↓, angioG↓, Ca+2↓, ROS↓, eff↓, Dose↓, eff↑, Mcl-1↓, HK2↓, IGF-1R↓, PTEN↑, citrate↓, Dose∅, eff↑, eff↑, eff↑, eff↑,
4772- CoQ10,    The anti-tumor activities of coenzyme Q0 through ROS-mediated autophagic cell death in human triple-negative breast cells
- in-vitro, BC, MDA-MB-468 - in-vitro, BC, MDA-MB-231
TumCP↓, Apoptosis↑, Casp3↑, cl‑PARP↑, LC3II↑, eff↓, TumCG↓, Bax:Bcl2↑, Beclin-1↑, TumAuto↑, ROS↑,
1980- CUR,  Rad,    Thioredoxin reductase-1 (TxnRd1) mediates curcumin-induced radiosensitization of squamous carcinoma cells
- in-vitro, Cerv, HeLa - in-vitro, Laryn, FaDu
selectivity↑, RadioS↑, TrxR↓, ROS↑, ERK↑, Dose∅, cl‑PARP↑,
136- CUR,  docx,    Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
Bcl-2↓, Bcl-xL↓, Mcl-1↓, BAX↑, BID↑, PARP↑, NF-kB↓, CDK1↓, COX2↓, RTK-RAS↓, PI3K/Akt↓, EGFR↓, HER2/EBBR2↓, P53↑, ChemoSen↑,
152- CUR,    Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer
- in-vivo, Pca, NA
β-catenin/ZEB1↓, AR↓, STAT3↓, p‑Akt↓, Mcl-1↓, Bcl-xL↓, cl‑PARP↑, miR-21↓, miR-205↑, TumCG↓, TumCP↓, TumCI↓, angioG↓, TumMeta↓,
118- CUR,    Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145
ROS↑, Bcl-2↓, PARP↑, cDC2↓, CycB/CCNB1↓, MDM2↓, eff↓, eIF2α↑, ATF4↑, CHOP↑, ER Stress↑, TumCCA↑,
132- CUR,    Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells
- in-vitro, Pca, PC3
TumCCA↑, ROS↑, TumAuto↑, UPR↑, ER Stress↑, Casp3↑, Casp9↑, Casp12↑, PARP↑, other↝, GRP78/BiP↑, PDI↑, eIF2α↑, other↝,
475- CUR,    Curcumin induces apoptotic cell death in human pancreatic cancer cells via the miR-340/XIAP signaling pathway
- in-vitro, PC, PANC1
Apoptosis↑, cl‑Casp3↑, miR-340↑, cl‑PARP↑, XIAP↓,
471- CUR,    Curcumin induces apoptotic cell death and protective autophagy by inhibiting AKT/mTOR/p70S6K pathway in human ovarian cancer cells
- in-vitro, Ovarian, SKOV3 - in-vitro, Ovarian, A2780S
Apoptosis↑, TumAuto↑, p62↓, p‑Akt↓, p‑mTOR↓, p‑P70S6K↓, Casp9↑, PARP↑, ATG3↑, Beclin-1↑, LC3‑Ⅱ/LC3‑Ⅰ↑,
462- CUR,    Curcumin promotes cancer-associated fibroblasts apoptosis via ROS-mediated endoplasmic reticulum stress
- in-vitro, Pca, PC3
Bcl-2↓, MMP↓, cl‑Casp3↑, BAX↑, BIM↑, p‑PARP↑, PUMA↑, p‑P53↑, ROS↑, p‑ERK↑, p‑eIF2α↑, CHOP↑, ATF4↑,
477- CUR,    Curcumin induces G2/M arrest and triggers autophagy, ROS generation and cell senescence in cervical cancer cells
- in-vitro, Cerv, SiHa
TumCP↓, TumCCA↑, Apoptosis↑, TumAuto↑, CycB/CCNB1↓, CDC25↓, ROS↑, p62↑, LC3‑Ⅱ/LC3‑Ⅰ↑, cl‑Casp3↑, cl‑PARP↑, P53↑, P21↑,
434- CUR,    Curcumin induces apoptosis in lung cancer cells by 14-3-3 protein-mediated activation of Bad
- in-vitro, Lung, A549
14-3-3 proteins↓, p‑BAD↓, p‑Akt↓, Akt↓, cl‑Casp9↑, cl‑PARP↑,
457- CUR,    Curcumin regulates proliferation, autophagy, and apoptosis in gastric cancer cells by affecting PI3K and P53 signaling
- in-vitro, GC, SGC-7901 - in-vitro, GC, BGC-823
TumCP↓, Apoptosis↑, TumAuto↑, P53↑, PI3K↓, P21↑, p‑Akt↓, p‑mTOR↓, Bcl-2↓, Bcl-xL↓, LC3I↓, BAX↑, Beclin-1↑, cl‑Casp3↑, cl‑PARP↑, LC3II↑, ATG3↑, ATG5↑,
448- CUR,    Heat shock protein 27 influences the anti-cancer effect of curcumin in colon cancer cells through ROS production and autophagy activation
- in-vitro, CRC, HT-29
Apoptosis↑, TumCCA↑, p‑Akt↓, Akt↓, Bcl-2↓, p‑BAD↓, BAD↑, cl‑PARP↑, ROS↑, HSP27↑, Beclin-1↑, p62↑, GPx1↓, GPx4↓,
4671- CUR,    Targeting colorectal cancer stem cells using curcumin and curcumin analogues: insights into the mechanism of the therapeutic efficacy
- in-vitro, CRC, NA
CSCs↓, TumCG↓, ChemoSen↑, Wnt↓, β-catenin/ZEB1↓, Shh↓, NOTCH↓, DNMT1↓, STAT3↓, NF-kB↓, EGFR↓, IGFR↓, TumCCA↓, cl‑PARP↑, BAX↑, ECM/TCF↓,
1871- DAP,    Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth
- in-vitro, AML, U937 - in-vivo, AML, NA
TumCP↓, Apoptosis↑, TumCG↓, PDK1↓, cl‑PARP↑, Bcl-xL↓, Bcl-2↓, Beclin-1↓, ATG3↓, PI3K↓, Akt↓, eff↑,
1864- DCA,  MET,    Dichloroacetate Enhances Apoptotic Cell Death via Oxidative Damage and Attenuates Lactate Production in Metformin-Treated Breast Cancer Cells
- in-vitro, BC, MCF-7 - in-vitro, BC, T47D - in-vitro, Nor, MCF10
PDKs↓, eff↑, ROS↑, PDK1↓, lactateProd↓, p‑PDH↑, Dose∅, OCR↑, DNA-PK↑, γH2AX↑, cl‑PARP↑, selectivity↑, *toxicity∅,
1605- EA,    Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence
- Review, Var, NA
*BioAv↓, antiOx↓, Inflam↓, TumCP↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, P53↑, P21↑, COX2↓, NF-kB↓, Akt↑, NOTCH↓, CDK2↓, CDK6↓, JAK↓, STAT3↓, EGFR↓, p‑ERK↓, p‑Akt↓, p‑STAT3↓, TGF-β↓, SMAD3↓, CDK6↓, Wnt/(β-catenin)↓, Myc↓, survivin↓, CDK8↓, PKCδ↓, tumCV↓, RadioS↑, eff↑, MDM2↓, XIAP↓, p‑RB1↓, PTEN↑, p‑FAK↓, Bax:Bcl2↑, Bcl-xL↓, Mcl-1↓, PUMA↑, NOXA↑, MMP↓, Cyt‑c↑, ROS↑, Ca+2↝, Endoglin↑, Diablo↑, AIF↑, iNOS↓, Casp9↑, Casp3↑, cl‑PARP↑, RadioS↑, Hif1a↓, HO-1↓, HO-2↓, SIRT1↓, selectivity↑, Dose∅, NHE1↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PDK1?, PDK1?, ECAR↝, COX1↓, Snail↓, Twist↓, cMyc↓, Telomerase↓, angioG↓, MMP2↓, MMP9↓, VEGF↓, Dose↝, PD-L1↓, eff↑, SIRT6↑, DNAdam↓,
1621- EA,    The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumMeta↓, TumCI↓, TumAuto↑, VEGFR2↓, MAPK↓, PI3K↓, Akt↓, PD-1↓, NOTCH↓, PCNA↓, Ki-67↓, cycD1/CCND1↓, CDK2↑, CDK6↓, Bcl-2↓, cl‑PARP↑, BAX↑, Casp3↑, DR4↑, DR5↑, Snail↓, MMP2↓, MMP9↓, TGF-β↑, PKCδ↓, β-catenin/ZEB1↓, SIRT1↓, HO-1↓, ROS↑, CHOP↑, Cyt‑c↑, MMP↓, OCR↓, AMPK↑, Hif1a↓, NF-kB↓, E-cadherin↑, Vim↓, EMT↓, LC3II↑, CIP2A↓, GLUT1↓, PDH↝, MAD↓, LDH↓, GSTs↑, NOTCH↓, survivin↓, XIAP↓, ER Stress↑, ChemoSideEff↓, ChemoSen↑,
27- EA,    Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice
- in-vivo, PC, PANC1
HH↓, Gli1↓, GLI2↓, CDK1/2/5/9↓, p‑Akt↓, NOTCH1↓, Shh↓, Snail↓, E-cadherin↑, NOTCH3↓, HEY1↓, TumCG↓, TumCP↓, Casp3↑, cl‑PARP↑, Bcl-2↓, cycD1/CCND1↓, CDK2↓, CDK6↓, BAX↑, COX2↓, Hif1a↓, VEGF↓, VEGFR2↓, IL6↓, IL8↓, MMP2↓, MMP9↓, NA↓,
26- EGCG,  QC,  docx,    Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy
- vitro+vivo, Pca, PC3
BAD↓, cl‑PARP↑, Casp7↑, IκB↓, Ki-67↓, VEGF↓, EGFR↓, FGF↓, TGF-β↓, TNF-α↓, SCF↓, Bax:Bcl2↑, NF-kB↓, chemoP↑, ChemoSen↑, TumVol↓,
989- EGCG,  Citrate,    In vitro and in vivo study of epigallocatechin-3-gallate-induced apoptosis in aerobic glycolytic hepatocellular carcinoma cells involving inhibition of phosphofructokinase activity
- in-vitro, HCC, NA - in-vivo, NA, NA
PFK↓, Glycolysis↓, lactateProd↓, GlucoseCon↓, TumCP↓, TumCCA↑, Casp3↑, cl‑PARP↑, Apoptosis↑, Casp8↑, Casp9↑, Cyt‑c↝, MMP↓, BAD↑, GLUT2↓, PKM2∅,
689- EGCG,    EGCG inhibited bladder cancer SW780 cell proliferation and migration both in vitro and in vivo via down regulation of NF-κB and MMP-9
- vitro+vivo, Bladder, SW780
Casp8↑, Casp9↑, Casp3↑, BAX↑, PARP↑, TumVol↓, NF-kB↓, MMP9↓,
680- EGCG,    Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea
- Review, NA, NA
NF-kB↓, STAT3↓, PI3K↓, HGF/c-Met↓, Akt↓, ERK↓, MAPK↓, AR↓, Casp↑, Ki-67↓, PARP↑, Bcl-2↓, BAX↑, PCNA↓, p27↑, P21↑,
3201- EGCG,    Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential
- Review, NA, NA
*AntiCan↑, *cardioP↑, *neuroP↑, *BioAv↝, *BioAv↓, *BioAv↓, *Dose↝, *Half-Life↝, *BioAv↑, *BBB↑, *hepatoP↓, *other↓, *Inflam↓, *NF-kB↓, *AP-1↓, *iNOS↓, *COX2↓, *ROS↓, *RNS↓, *IL8↓, *JAK↓, *PDGFR-BB↓, *IGF-1R↓, *MMP2↓, *P53↓, *NRF2↑, *TNF-α↓, *IL6↓, *E2Fs↑, *SOD1↑, *SOD2↑, Casp3↑, Cyt‑c↑, PARP↑, DNMTs↓, Telomerase↓, Hif1a↓, MMPs↓, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, P53↑, PTEN↑, TumCP↓, MAPK↓, HGF/c-Met↓, TIMP1↑, HDAC↓, MMP9↓, uPA↓, GlutMet↓, ChemoSen↑, chemoP↑,
3205- EGCG,    The Role of Epigallocatechin-3-Gallate in Autophagy and Endoplasmic Reticulum Stress (ERS)-Induced Apoptosis of Human Diseas
- Review, Var, NA - Review, AD, NA
Beclin-1↑, ROS↑, Apoptosis↑, ER Stress↑, *Inflam↓, *cardioP↑, *antiOx↑, *LDL↓, *NF-kB↓, *MPO↓, *glucose↓, *ROS↓, ATG5↑, LC3B↑, MMP↑, lactateProd↓, VEGF↓, Zeb1↑, Wnt↑, IGF-1R↑, Fas↑, Bak↑, BAD↑, TP53↓, Myc↓, Casp8↓, LC3II↑, NOTCH3↓, eff↑, p‑Akt↓, PARP↑, *Cyt‑c↓, *BAX↓, *memory↑, *neuroP↑, *Ca+2?, GRP78/BiP↑, CHOP↑, ATF4↑, Casp3↑, Casp8↑, UPR↑,
3206- EGCG,    Insights on the involvement of (-)-epigallocatechin gallate in ER stress-mediated apoptosis in age-related macular degeneration
- Review, AMD, NA
*Ca+2↓, *ROS↓, *Apoptosis↓, *GRP78/BiP↓, *CHOP↓, *PERK↓, *IRE1↓, *p‑PARP↓, *Casp3↓, *Casp12↓, *ER Stress↓, *UPR↓,
1516- EGCG,    Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential
- Review, NA, NA
*Dose∅, Half-Life∅, BioAv∅, BBB↑, toxicity∅, eff↓, Apoptosis↑, Casp3↑, Cyt‑c↑, cl‑PARP↑, DNMTs↓, Telomerase↓, angioG↓, Hif1a↓, NF-kB↓, MMPs↓, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, P53↑, PTEN↑, IGF-1↓, H3↓, HDAC1↓, *LDH↓, *ROS↓,
5225- EMD,    Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3
- vitro+vivo, HCC, HepG2 - in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7
STAT3↓, Akt↓, cSrc↓, JAK1↓, JAK2↓, SHP1↑, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, Mcl-1↓, survivin↓, VEGF↓, TumCP↓, Casp3↑, cl‑PARP↑, ChemoSen↑, XIAP↓,
5223- EMD,    Emodin inhibits colon cancer by altering BCL-2 family proteins and cell survival pathways
- in-vitro, CRC, DLD1 - in-vitro, Nor, CCD841
tumCV↓, Apoptosis↑, selectivity↑, Casp↑, Bcl-2↓, MMP↓, TumCD↑, MAPK↓, JNK↓, PI3K↓, Akt↓, NF-kB↓, STAT↓, Diff↓, P53↑, PARP↓,
1332- EMD,    Induction of Apoptosis in HepaRG Cell Line by Aloe-Emodin through Generation of Reactive Oxygen Species and the Mitochondrial Pathway
- in-vivo, Nor, HepaRG
*tumCV↓, *ROS↑, *MMP↓, *Fas↑, *P53↑, *P21↑, *Bax:Bcl2↑, *Casp3↑, *Casp8↑, *Casp9↑, *cl‑PARP↑, *TumCCA↑, *P21↑, *cycE/CCNE↑, *cycA1/CCNA1↓, *CDK2↓,
1318- EMD,    Aloe-emodin Induces Apoptosis in Human Liver HL-7702 Cells through Fas Death Pathway and the Mitochondrial Pathway by Generating Reactive Oxygen Species
- in-vitro, Nor, HL7702
*TumCCA↑, *ROS↑, *MMP↓, *Fas↑, *P53↑, *P21↓, *Bax:Bcl2↑, *cl‑Casp3↑, *cl‑Casp8↑, *cl‑Casp9↑, *cl‑PARP↑,
1331- EMD,    Aloe-emodin induces apoptosis of human nasopharyngeal carcinoma cells via caspase-8-mediated activation of the mitochondrial death pathway
- in-vitro, NPC, NA
TumCCA↑, CycB/CCNB1↑, DNAdam↑, Casp3↑, cl‑PARP↑, MMP↓, Ca+2↑, ROS↑,
1155- F,    The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations
- Review, NA, NA
*toxicity↓, Casp3↑, Casp7↑, Casp8↑, Casp9↑, VEGF↓, angioG↓, PI3K↓, Akt↓, PARP↑, Bak↑, BID↑, Fas↑, Mcl-1↓, survivin↓, XIAP↓, ERK↓, EMT↓, EM↑, IM↓, Snail↓, Slug↓, Twist↓,
1656- FA,    Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling
- Review, Var, NA
tyrosinase↓, CK2↓, TumCP↓, TumCMig↓, FGF↓, FGFR1↓, PI3K↓, Akt↓, VEGF↓, FGFR1↓, FGFR2↓, PDGF↓, ALAT↓, AST↓, TumCCA↑, CDK2↓, CDK4↓, CDK6↓, BAX↓, Bcl-2↓, MMP2↓, MMP9↓, P53↑, PARP↑, PUMA↑, NOXA↑, Casp3↑, Casp9↑, TIMP1↑, lipid-P↑, mtDam↑, EMT↓, Vim↓, E-cadherin↓, p‑STAT3↓, COX2↓, CDC25↓, RadioS↑, ROS↑, DNAdam↑, γH2AX↑, PTEN↑, LC3II↓, Beclin-1↓, SOD↓, Catalase↓, GPx↓, Fas↑, *BioAv↓, cMyc↓, Beclin-1↑, LC3‑Ⅱ/LC3‑Ⅰ↓,
2855- FIS,    Fisetin Induces Apoptosis Through p53-Mediated Up-Regulation of DR5 Expression in Human Renal Carcinoma Caki Cells
- in-vitro, RCC, Caki-1
TumCCA↑, cl‑PARP↑, Apoptosis↑, Casp↑, P53↑, DR5↑, CHOP↑, ROS↑, ER Stress↑, ATF4↑, XBP-1↑, eff∅,
2857- FIS,    A review on the chemotherapeutic potential of fisetin: In vitro evidences
- Review, Var, NA
COX2↓, PGE2↓, EGFR↓, Wnt↓, β-catenin/ZEB1↓, TCF↑, Apoptosis↑, Casp3↑, cl‑PARP↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, Akt↓, mTOR↓, ACC↑, Cyt‑c↑, Diablo↑, cl‑Casp8↑, Fas↑, DR5↑, TRAIL↑, Securin↓, CDC2↓, CDC25↓, HSP70/HSPA5↓, CDK2↓, CDK4↓, cycD1/CCND1↓, MMP2↓, uPA↓, NF-kB↓, cFos↓, cJun↓, MEK↓, p‑ERK↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↓, NF-kB↑, ROS↑, DNAdam↑, MMP↓, CHOP↑, eff↑, ChemoSen↑,
2845- FIS,    Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, p38↓, *antiOx↑, *neuroP↑, Casp3↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, AMPK↑, ACC↑, DNAdam↑, MMP↓, eff↑, ROS↑, cl‑PARP↑, Cyt‑c↑, Diablo↑, P53↑, p65↓, Myc↓, HSP70/HSPA5↓, HSP27↓, COX2↓, Wnt↓, EGFR↓, NF-kB↓, TumCCA↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycA1/CCNA1↓, P21↑, MMP2↓, MMP9↓, TumMeta↓, MMP1↓, MMP3↓, MMP7↓, MET↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↑, uPA↓, ChemoSen↑, EMT↓, Twist↓, Zeb1↓, cFos↓, cJun↓, EGF↓, angioG↓, VEGF↓, eNOS↓, *NRF2↑, HO-1↑, NRF2↓, GSTs↓, ATF4↓,
2824- FIS,    Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics
- Review, Var, NA
*antiOx↑, *Inflam↓, angioG↓, BioAv↓, BioAv↑, TumCP↓, TumCI↓, TumCMig↓, *neuroP↑, EMT↓, ROS↑, selectivity↑, EGFR↓, NF-kB↓, VEGF↓, MMP9↓, MMP↓, cl‑PARP↑, Casp7↑, Casp8↑, Casp9↑, *ROS↓, uPA↓, MMP1↓, Wnt↓, Akt↓, PI3K↓, ERK↓, Half-Life↝,
2825- FIS,    Exploring the molecular targets of dietary flavonoid fisetin in cancer
- Review, Var, NA
*Inflam↓, *antiOx↓, *ERK↑, *p‑cMyc↑, *NRF2↑, *GSH↑, *HO-1↑, mTOR↓, PI3K↓, Akt↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, P21↑, p27↑, JNK↑, MMP2↓, MMP9↓, uPA↓, NF-kB↓, cFos↓, cJun↓, E-cadherin↑, Vim↓, N-cadherin↓, EMT↓, MMP↓, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, P53↑, COX2↓, PGE2↓, HSP70/HSPA5↓, HSP27↓, DNAdam↑, Casp3↑, Casp9↑, ROS↑, AMPK↑, NO↑, Ca+2↑, mTORC1↓, p70S6↓, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, eff↑, eff↑, eff↑, RadioS↑, ChemoSen↑, Half-Life↝,
2827- FIS,    The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment
- Review, Var, NA
*antiOx↑, *Inflam↓, neuroP↑, hepatoP↑, RenoP↑, cycD1/CCND1↓, TumCCA↑, MMPs↓, VEGF↓, MAPK↓, NF-kB↓, angioG↓, Beclin-1↑, LC3s↑, ATG5↑, Bcl-2↓, BAX↑, Casp↑, TNF-α↓, Half-Life↓, MMP↓, mt-ROS↑, cl‑PARP↑, CDK2↓, CDK4↓, Cyt‑c↑, Diablo↑, DR5↑, Fas↑, PCNA↓, Ki-67↓, p‑H3↓, chemoP↑, Ca+2↑, Dose↝, CDC25↓, CDC2↓, CHK1↑, Chk2↑, ATM↑, PCK1↓, RAS↓, p‑p38↓, Rho↓, uPA↓, MMP7↓, MMP13↓, GSK‐3β↑, E-cadherin↑, survivin↓, VEGFR2↓, IAP2↓, STAT3↓, JAK1↓, mTORC1↓, mTORC2↓, NRF2↑,
2828- FIS,    Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review
- Review, Var, NA
*neuroP↑, *antiOx↑, *Inflam↓, RenoP↑, COX2↓, Wnt↓, EGFR↓, NF-kB↓, Casp3↑, Ca+2↑, Casp8↑, TumCCA↑, CDK1↓, PI3K↓, Akt↓, mTOR↓, MAPK↓, *P53↓, *P21↓, *p16↓, mTORC1↓, mTORC2↓, P53↑, P21↑, cycD1/CCND1↓, cycA1/CCNA1↓, CDK2↓, CDK4↓, BAX↑, Bcl-2↓, PCNA↓, HER2/EBBR2↓, Cyt‑c↑, MMP↓, cl‑Casp9↑, MMP2↓, MMP9↓, cl‑PARP↑, uPA↓, DR4↑, DR5↑, ROS↓, AIF↑, CDC25↓, Dose↑, CHOP↑, ROS↑, cMyc↓, cardioP↑,
2829- FIS,    Fisetin: An anticancer perspective
- Review, Var, NA
TumCP↓, TumCI↓, TumCCA↑, TumCG↓, Apoptosis↑, cl‑PARP↑, PKCδ↓, ROS↓, ERK↓, NF-kB↓, survivin↓, ROS↑, PI3K↓, Akt↓, mTOR↓, MAPK↓, p38↓, HER2/EBBR2↓, EMT↓, PTEN↑, HO-1↑, NRF2↑, MMP2↓, MMP9↓, MMP↓, Casp8↑, Casp9↑, TRAILR↑, Cyt‑c↑, XIAP↓, P53↑, CDK2↓, CDK4↓, CDC25↓, CDC2↓, VEGF↓, DNAdam↑, TET1↓, CHOP↑, CD44↓, CD133↓, uPA↓, CSCs↓,

Showing Research Papers: 101 to 150 of 285
Prev Page 3 of 6 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 285

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

NA↓, 1,  

Redox & Oxidative Stress ⓘ

antiOx↓, 1,   Catalase↓, 1,   Fenton↑, 1,   GPx↓, 1,   GPx1↓, 1,   GPx4↓, 1,   GSH↓, 1,   GSTs↓, 1,   GSTs↑, 1,   HO-1↓, 3,   HO-1↑, 2,   HO-2↓, 1,   lipid-P↑, 2,   MAD↓, 1,   NRF2↓, 3,   NRF2↑, 2,   OXPHOS↓, 1,   ROS↓, 4,   ROS↑, 23,   mt-ROS↑, 1,   SOD↓, 1,   TrxR↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 2,   ATP↓, 1,   CDC2↓, 3,   CDC25↓, 6,   EGF↓, 1,   FGFR1↓, 2,   MEK↓, 1,   MMP↓, 14,   MMP↑, 2,   mtDam↑, 1,   OCR↓, 1,   OCR↑, 1,   SDH↓, 1,   XIAP↓, 8,  

Core Metabolism/Glycolysis ⓘ

ACC↑, 2,   ALAT↓, 2,   AMPK↑, 3,   ATG7↑, 1,   citrate↓, 1,   cMyc↓, 3,   CPT1A↓, 1,   ECAR↝, 1,   FASN↑, 1,   FBPase↑, 1,   glucoNG↑, 1,   GlucoseCon↓, 2,   GLUT2↓, 1,   GlutMet↓, 1,   Glycolysis↓, 4,   HK2↓, 3,   lactateProd↓, 4,   LDH↓, 2,   LDL↓, 1,   PCK1↓, 1,   PDH↓, 2,   PDH↝, 1,   p‑PDH↑, 1,   PDK1?, 2,   PDK1↓, 3,   PDKs↓, 1,   PFK↓, 2,   PFK2?, 1,   PI3K/Akt↓, 1,   PKM2↓, 1,   PKM2∅, 1,   PPARα↓, 1,   SIRT1↓, 2,   TCA↓, 2,   β-oxidation↓, 2,  

Cell Death ⓘ

14-3-3 proteins↓, 1,   Akt↓, 18,   Akt↑, 1,   p‑Akt↓, 8,   Apoptosis↑, 19,   BAD↓, 1,   BAD↑, 5,   p‑BAD↓, 2,   Bak↑, 4,   BAX↓, 1,   BAX↑, 14,   Bax:Bcl2↑, 3,   Bcl-2↓, 18,   Bcl-xL↓, 9,   BID↑, 2,   BIM↑, 3,   Casp↑, 5,   Casp12↑, 1,   Casp2↑, 1,   Casp3↑, 22,   cl‑Casp3↑, 6,   Casp7↑, 3,   Casp8↓, 1,   Casp8↑, 8,   cl‑Casp8↑, 1,   Casp9↑, 13,   cl‑Casp9↑, 2,   Chk2↑, 1,   CK2↓, 1,   Cyt‑c↑, 11,   Cyt‑c↝, 1,   Diablo↑, 5,   DR4↑, 2,   DR5↑, 5,   Fas↑, 5,   HEY1↓, 1,   HGF/c-Met↓, 2,   hTERT/TERT↓, 1,   IAP2↓, 1,   iNOS↓, 2,   JNK↓, 1,   JNK↑, 1,   MAPK↓, 7,   Mcl-1↓, 10,   MDM2↓, 2,   Myc↓, 3,   NOXA↑, 2,   p27↑, 2,   p38↓, 2,   p‑p38↓, 1,   PUMA↑, 3,   survivin↓, 7,   Telomerase↓, 3,   TRAIL↑, 1,   TRAILR↑, 1,   TumCD↑, 1,  

Kinase & Signal Transduction ⓘ

CaMKII ↓, 1,   cSrc↓, 1,   HER2/EBBR2↓, 3,   p70S6↓, 1,   RTK-RAS↓, 1,  

Transcription & Epigenetics ⓘ

cJun↓, 3,   H3↓, 1,   p‑H3↓, 1,   miR-205↑, 1,   miR-21↓, 1,   other↝, 2,   tumCV↓, 3,  

Protein Folding & ER Stress ⓘ

CHOP↑, 8,   eIF2α↑, 2,   p‑eIF2α↑, 2,   ER Stress↑, 7,   GRP78/BiP↑, 4,   HSP27↓, 2,   HSP27↑, 1,   HSP70/HSPA5↓, 3,   IRE1↑, 1,   UPR↑, 3,   XBP-1↓, 1,   XBP-1↑, 1,  

Autophagy & Lysosomes ⓘ

ATG3↓, 1,   ATG3↑, 2,   ATG5↑, 4,   Beclin-1↓, 2,   Beclin-1↑, 8,   LC3‑Ⅱ/LC3‑Ⅰ↓, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 3,   LC3B↑, 1,   LC3I↓, 1,   LC3II↓, 1,   LC3II↑, 4,   LC3s↑, 1,   p62↓, 2,   p62↑, 2,   TumAuto↑, 7,  

DNA Damage & Repair ⓘ

ATM↑, 1,   CHK1↑, 1,   DNA-PK↑, 1,   DNAdam↓, 1,   DNAdam↑, 7,   DNMT1↓, 1,   DNMTs↓, 2,   P53↑, 14,   p‑P53↑, 1,   PARP↓, 1,   PARP↑, 11,   p‑PARP↑, 1,   cl‑PARP↑, 33,   PCNA↓, 4,   SIRT6↑, 1,   TP53↓, 1,   γH2AX↑, 2,  

Cell Cycle & Senescence ⓘ

CDK1↓, 2,   CDK1/2/5/9↓, 1,   CDK2↓, 10,   CDK2↑, 1,   CDK4↓, 7,   cycA1/CCNA1↓, 2,   CycB/CCNB1↓, 2,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 11,   cycE/CCNE↓, 2,   P21↑, 8,   p‑RB1↓, 1,   Securin↓, 1,   TumCCA↓, 1,   TumCCA↑, 15,  

Proliferation, Differentiation & Cell State ⓘ

CD133↓, 1,   CD44↓, 1,   cDC2↓, 1,   CDK8↓, 1,   cFos↓, 3,   CIP2A↓, 1,   CSCs↓, 2,   Diff↓, 1,   EMT↓, 8,   ERK↓, 5,   ERK↑, 1,   p‑ERK↓, 2,   p‑ERK↑, 1,   FGF↓, 2,   FGFR2↓, 1,   Gli1↓, 1,   GSK‐3β↑, 1,   HDAC↓, 2,   HDAC1↓, 1,   HDAC8↓, 1,   HH↓, 1,   IGF-1↓, 1,   IGF-1R↓, 1,   IGF-1R↑, 1,   IGFR↓, 1,   mTOR↓, 7,   p‑mTOR↓, 2,   mTORC1↓, 3,   mTORC2↓, 2,   NOTCH↓, 4,   NOTCH↑, 1,   NOTCH1↓, 1,   NOTCH1↑, 1,   NOTCH3↓, 2,   p‑P70S6K↓, 1,   PI3K↓, 12,   PTEN↑, 6,   RAS↓, 1,   SCF↓, 2,   Shh↓, 2,   SHP1↑, 1,   STAT↓, 1,   STAT3↓, 8,   p‑STAT3↓, 2,   TCF↑, 1,   TOP1↓, 1,   TumCG↓, 7,   tyrosinase↓, 1,   Wnt↓, 5,   Wnt↑, 1,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

Ca+2↓, 2,   Ca+2↑, 5,   Ca+2↝, 1,   CLDN1↓, 1,   E-cadherin↓, 2,   E-cadherin↑, 6,   EM↑, 1,   p‑FAK↓, 1,   Fibronectin↓, 3,   GLI2↓, 1,   Ki-67↓, 4,   MET↓, 1,   miR-340↑, 1,   MMP-10↓, 1,   MMP1↓, 2,   MMP13↓, 1,   MMP2↓, 10,   MMP3↓, 1,   MMP7↓, 2,   MMP9↓, 12,   MMPs↓, 3,   N-cadherin↓, 3,   PDGF↓, 1,   PKCδ↓, 3,   Rho↓, 1,   Slug↓, 2,   SMAD3↓, 1,   Snail↓, 7,   TET1↓, 1,   TET1↑, 1,   TGF-β↓, 2,   TGF-β↑, 1,   TIMP1↑, 2,   TumCI↓, 5,   TumCMig↓, 2,   TumCP↓, 15,   TumMeta↓, 3,   TumMeta↑, 1,   Twist↓, 4,   uPA↓, 8,   Vim↓, 6,   Zeb1↓, 1,   Zeb1↑, 1,   β-catenin/ZEB1↓, 4,  

Angiogenesis & Vasculature ⓘ

angioG↓, 10,   ATF4↓, 1,   ATF4↑, 5,   ECM/TCF↓, 1,   EGFR↓, 9,   Endoglin↑, 1,   eNOS↓, 1,   Hif1a↓, 8,   NO↑, 1,   PDI↑, 1,   VEGF↓, 13,   VEGFR2↓, 3,  

Barriers & Transport ⓘ

BBB↑, 1,   GLUT1↓, 2,   NHE1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 1,   COX2↓, 8,   COX2↑, 1,   IL10↓, 1,   IL1β↓, 1,   IL6↓, 2,   IL8↓, 1,   Inflam↓, 2,   IκB↓, 1,   JAK↓, 1,   JAK1↓, 2,   JAK2↓, 1,   NF-kB↓, 16,   NF-kB↑, 1,   p65↓, 1,   PD-1↓, 1,   PD-L1↓, 1,   PGE2↓, 3,   T-Cell↝, 1,   TLR4↓, 1,   TNF-α↓, 3,  

Cellular Microenvironment ⓘ

IM↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,   CDK6↓, 6,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 2,   BioAv∅, 1,   ChemoSen↑, 11,   Dose↓, 1,   Dose↑, 1,   Dose↝, 2,   Dose∅, 4,   eff↓, 4,   eff↑, 17,   eff∅, 1,   Half-Life↓, 1,   Half-Life↝, 2,   Half-Life∅, 1,   RadioS↑, 6,   selectivity↑, 7,  

Clinical Biomarkers ⓘ

ALAT↓, 2,   ALP↓, 1,   AR↓, 2,   AST↓, 1,   EGFR↓, 9,   HER2/EBBR2↓, 3,   hTERT/TERT↓, 1,   IL6↓, 2,   Ki-67↓, 4,   LDH↓, 2,   Myc↓, 3,   PD-L1↓, 1,   TP53↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   cardioP↑, 2,   chemoP↑, 3,   chemoPv↑, 1,   ChemoSideEff↓, 1,   hepatoP↑, 1,   neuroP↑, 2,   RenoP↑, 3,   toxicity∅, 1,   TumVol↓, 2,  
Total Targets: 372

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 6,   Catalase↑, 1,   GSH↑, 3,   GSTs↑, 1,   HO-1↑, 2,   MPO↓, 1,   NOX4↓, 1,   NRF2↑, 4,   RNS↓, 1,   ROS↓, 6,   ROS↑, 2,   SOD↑, 1,   SOD1↑, 1,   SOD2↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 2,  

Core Metabolism/Glycolysis ⓘ

p‑cMyc↑, 1,   GAPDH↑, 1,   glucose↓, 1,   LDH↓, 1,   LDL↓, 1,   NADPH↑, 1,  

Cell Death ⓘ

Apoptosis↓, 1,   BAX↓, 2,   Bax:Bcl2↑, 2,   Bcl-2↑, 1,   Casp12↓, 1,   Casp3↓, 2,   Casp3↑, 1,   cl‑Casp3↑, 1,   Casp8↑, 1,   cl‑Casp8↑, 1,   Casp9↑, 1,   cl‑Casp9↑, 1,   Cyt‑c↓, 2,   Fas↑, 2,   iNOS↓, 2,  

Transcription & Epigenetics ⓘ

other↓, 1,   tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↓, 1,   ER Stress↓, 1,   GRP78/BiP↓, 1,   HSP70/HSPA5↑, 1,   IRE1↓, 1,   PERK↓, 1,   UPR↓, 1,  

DNA Damage & Repair ⓘ

p16↓, 1,   P53↓, 2,   P53↑, 2,   PARP↓, 1,   p‑PARP↓, 1,   cl‑PARP↑, 2,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   cycA1/CCNA1↓, 1,   cycE/CCNE↑, 1,   E2Fs↑, 1,   P21↓, 2,   P21↑, 2,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

ERK↑, 1,   IGF-1R↓, 1,  

Migration ⓘ

AP-1↓, 1,   Ca+2?, 1,   Ca+2↓, 1,   MMP2↓, 1,  

Angiogenesis & Vasculature ⓘ

PDGFR-BB↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 6,   JAK↓, 1,   NF-kB↓, 4,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 4,   BioAv↑, 1,   BioAv↝, 1,   Dose↝, 1,   Dose∅, 1,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

AST↓, 1,   IL6↓, 1,   LDH↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   cardioP↑, 3,   hepatoP↓, 1,   memory↑, 1,   neuroP↑, 5,   toxicity↓, 2,   toxicity∅, 1,  
Total Targets: 90

Scientific Paper Hit Count for: PARP, poly ADP-ribose polymerase (PARP) cleavage
16 Apigenin (mainly Parsley)
15 Curcumin
14 Thymoquinone
12 Baicalein
12 Quercetin
12 Fisetin
10 Sulforaphane (mainly Broccoli)
8 EGCG (Epigallocatechin Gallate)
8 Shikonin
7 Ashwagandha(Withaferin A)
7 Berberine
7 Capsaicin
6 Boswellia (frankincense)
6 Carnosic acid
6 Garcinol
6 Honokiol
6 Piperlongumine
6 Vitamin C (Ascorbic Acid)
5 Metformin
5 Betulinic acid
5 Chrysin
5 Emodin
5 Silymarin (Milk Thistle) silibinin
4 doxorubicin
4 Bufalin/Huachansu
4 Carvacrol
4 Citric Acid
4 Gambogic Acid
4 Propolis -bee glue
4 Phenethyl isothiocyanate
4 Resveratrol
3 Auranofin
3 Allicin (mainly Garlic)
3 Cisplatin
3 Brucea javanica
3 Thymol-Thymus vulgaris
3 Docetaxel
3 Ellagic acid
3 Magnetic Fields
3 Propyl gallate
2 Silver-NanoParticles
2 5-fluorouracil
2 Artemisinin
2 Berbamine
2 temozolomide
2 brusatol
2 Boron
2 Radiotherapy/Radiation
2 HydroxyTyrosol
2 Juglone
2 Luteolin
2 Lycopene
2 Magnolol
2 Nimbolide
2 Phenylbutyrate
2 Paclitaxel
2 Piperine
2 Rosmarinic acid
2 salinomycin
2 Selenite (Sodium)
2 Ursolic acid
2 Urolithin
1 3-bromopyruvate
1 immunotherapy
1 Atorvastatin
1 Aloe anthraquinones
1 Baicalin
1 almonertinib
1 Bromelain
1 Butyrate
1 Sorafenib (brand name Nexavar)
1 Cat’s Claw
1 Celastrol
1 Chlorogenic acid
1 Chlorophyllin
1 Coenzyme Q10
1 Dichloroacetophenone(2,2-)
1 Dichloroacetate
1 Fucoidan
1 Ferulic acid
1 Gallic acid
1 Gemcitabine (Gemzar)
1 Graviola
1 Hydroxycinnamic-acid
1 hydroxychloroquine
1 lambertianic acid
1 Methylene blue
1 Photodynamic Therapy
1 Chemotherapy
1 Myricetin
1 nelfinavir/Viracept
1 Oleuropein
1 SonoDynamic Therapy UltraSound
1 Hyperthermia
1 Plumbagin
1 VitK3,menadione
1 Hyperoside
1 Selenium NanoParticles
1 chitosan
1 Folic Acid, Vit B9
1 Osimertinib
1 Adagrasib
1 Aflavin-3,3′-digallate
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:239  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page